x C57BL/6 6) F1 (CB6F1) mice and human pancreatic adenocarcinoma, CAPAN-1, xenografts in athymic nude mice. Administration (i.p.) of AMP or ATP in large volumes of saline resulted in increases in levels of ATP in whole blood (cellular) and the plasma compartment (extracellular). Treatment of mice with AMP or ATP yielded increases in plasma levels of ATP from a basal level of about 0.8 1LM to 2-5 ktM.These expanded ATP pools were achieved for several hours after a single i.p. injection of AMP or ATP and were obtained without long-lasting toxicity toward the host (5). We suggested that the extracellular ATP generated in the blood plasma of tumor-bearing hosts affects the growth of tumor cells by mechanisms that were identified by the in vitro studies (1-4), although host-mediated mechanisms cannot be ruled out, since ATP is known to influence several physiological systems that may affect tumor growth (6).We now have identified a biological mechanism that accounts for the generation of increased blood plasma ATP concentrations after i.p. administration of AMP or ATP (but not adenosine) into mice. The potential clinical utility ofAMP or ATP treatments is demonstrated by the significant inhibition of CT26 colon adenocarcinoma growth in CB6F1 mice when the treatment is initiated after the tumors became palpable. In addition, an unexpected effect of adenine nucleotides is their ability to slow the rate of weight loss in mice bearing relatively large CT26 tumors. This phenomenon is not related to the tumor growth-inhibitory effects of these compounds and may be related to an effective introduction of purines into the host and their effective distribution into host tissues, thus slowing down the nutritional depletion of host compartments by the fast-growing tumor (7).
MATERIALS AND METHODSSolutions of nucleotides in saline were prepared as described (5). Culture conditions of CT26 cells and tumor inoculations in CB6F1 mice (The Jackson Laboratory) followed published procedures (5).Experimental Protocol. Tumors were inoculated by injections of 2.5 x 105 CT26 cells (>90% viability) in 50 /.l of phosphate-buffered saline into the right hind footpad of CB6F1 mice. Treatments were initiated at a variety of times after inoculation of the tumors. The injection schedules started either 1 or 5 days after tumor inoculation (when none of the tumors were palpable) or when the tumors were clearly palpable (average calculated weight of 100 mg), which occurred in 100% of the inoculated mice after 8-11 days. Mice were randomized, divided into groups, and injected daily with 2.2 ml of saline, adenosine, AMP, or ATP (compounds were in sterile saline solutions at concentrations of 25 mM, with AMP and ATP solutions adjusted to pH 6.2). Injections were administered i.p. with 30-gauge needles, and mice were lightly anesthetized with ether. Mice were weighed, and tumor sizes were measured before the start of the treatment schedule and every 3 days during and after the treatment schedule. These determinations were performed before injections du...